Stock listing

Munich:9II Biovica International AB Aktie

German listing (Munich) of Biovica International AB · home listing Stockholm:BIOVICB

Follow Biovica International AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:BIOVIC_B

0.328 SEK -0.012 (-3.5%)

Close on Nov 4, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:BIOVIC_B

Past year -33.3% · daily closes, Nov 4, 2025 – Nov 4, 2026, adjusted for splits
Day range
0.304 – 0.355 SEKNov 4, 2026
Volume
194,164 sharesNov 4, 2026
Market cap
122.9M SEKAt the close on Nov 4, 2026 · price × 374.8M shares outstanding
52-week range
0.270 – 0.610 SEKLowest and highest trades, Nov 5, 2025 – Nov 4, 2026
Traded on an average day
195,609 SEKMedian day 344,523 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Biovica International AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Frankfurt:9II€0.018 EUR+0.000 (+1.1%)—€0.018€0.018€0.018€0.018Close on Oct 27, 2026

Daily closes

Last 3 months, Aug 4, 2026 – Nov 4, 2026 · OMXSTO:BIOVIC_B · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.328-0.012-3.5%0.3210.3550.304194,164
0.340-0.008-2.3%0.3400.3580.301176,631
0.348-0.011-3.1%0.3590.3700.340387,337
0.359-0.012-3.2%0.3740.3740.350165,272
0.371+0.051+15.9%0.3250.3750.320230,921
0.320-0.006-1.8%0.3270.3390.32086,409
0.326+0.010+3.2%0.3100.3260.298515,475
0.316+0.019+6.4%0.3370.3390.308318,101
0.297-0.007-2.3%0.2950.3190.28840,365
0.304-0.002-0.7%0.3010.3060.294655,433
0.306-0.004-1.3%0.3100.3100.29630,930
0.310+0.013+4.4%0.3020.3100.29749,504
0.297-0.005-1.7%0.3010.3100.296413,056
0.302+0.007+2.4%0.2990.3020.294106,896
0.2950.0000.0%0.2950.2950.29320,249
0.295-0.001-0.3%0.2970.3030.290741,810
0.296-0.002-0.7%0.3030.3040.296344,523
0.298-0.005-1.7%0.2960.3040.29670,085
0.303+0.003+1.0%0.3000.3070.29417,980
0.300+0.008+2.7%0.2910.3060.29169,997
0.292-0.012-3.9%0.3000.3090.291982,857
0.304+0.007+2.4%0.2920.3040.292170,433
0.297-0.010-3.3%0.3070.3070.290374,730
0.307+0.007+2.3%0.3000.3090.294306,077
0.300-0.004-1.3%0.3040.3040.295222,870
0.304-0.006-1.9%0.3100.3100.297250,272
0.310+0.003+1.0%0.3070.3140.299232,832
0.307-0.007-2.2%0.3140.3140.304398,404
0.314+0.001+0.3%0.3150.3150.300258,847
0.313+0.004+1.3%0.3020.3150.298247,803
0.309-0.007-2.2%0.3160.3160.30828,478
0.316+0.013+4.3%0.3120.3170.2792,038,338
0.303-0.013-4.1%0.3090.3190.3001,641,812
0.316+0.006+1.9%0.3250.3250.309129,079
0.310+0.004+1.3%0.3130.3200.3001,418,777
0.306-0.002-0.6%0.3000.3140.296739,124
0.3080.0000.0%0.3050.3110.300793,636
0.3080.0000.0%0.3040.3200.304564,739
0.308-0.021-6.4%0.3150.3150.301997,818
0.329-0.091-21.7%0.3000.3480.3004,765,024
0.4200.0000.0%0.4200.4320.419769,951
0.420-0.001-0.2%0.4230.4470.416666,719
0.4210.0000.0%0.4200.4300.411464,709
0.421-0.002-0.5%0.4300.4300.416140,230
0.423-0.007-1.6%0.4300.4300.421142,216
0.430-0.007-1.6%0.4300.4400.400515,364
0.437-0.013-2.9%0.4490.4490.430589,191
0.450+0.016+3.7%0.4330.4650.4301,293,815
0.434+0.002+0.5%0.4460.4460.428591,340
0.432-0.014-3.1%0.4500.4510.4301,168,563
0.446-0.004-0.9%0.4460.4500.437763,928
0.450+0.013+3.0%0.4370.4500.432302,362
0.437-0.011-2.5%0.4430.4500.424204,242
0.448-0.022-4.7%0.4780.4780.436629,323
0.470-0.012-2.5%0.4740.5000.452844,975
0.482-0.011-2.2%0.4870.5180.470518,378
0.493-0.029-5.6%0.5160.5160.48577,240
0.522+0.002+0.4%0.5180.5240.482272,043
0.520-0.010-1.9%0.5280.5280.475525,709
0.530+0.006+1.1%0.5280.5380.500686,676
0.524-0.002-0.4%0.5480.5480.516117,954
0.526-0.024-4.4%0.5520.5520.516682,712
0.550-0.002-0.4%0.5540.5700.526205,931
0.552+0.006+1.1%0.5480.5600.530442,370
0.546+0.038+7.5%0.5080.5580.508749,856
0.508+0.006+1.2%0.5020.5360.502223,822
0.502+0.002+0.4%0.5240.5240.497189,635
Ticker
Munich:9II
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Biovica International (Stockholm:BIOVIC B) Q1 2027 Earnings Call

    Thu, Sep 10, 2026 · 9:00 AM ET

    Watch Transcript

  • Biovica International (Stockholm:BIOVIC B) Q3 2026 Earnings Call

    Wed, Mar 18, 2026 · 9:00 AM ET

    Watch Transcript

  • Biovica International (Stockholm:BIOVIC B) Q1 2026 Earnings Call

    Thu, Sep 11, 2025 · 9:00 AM ET

    Watch Transcript

Latest news

Announcement from the Annual General Meeting in Biovica International AB

Sep 16, 2026

Closed 0.31 (+1.3%) on Sep 17, 2026

Biovica Resolves on a Fully Guaranteed Rights Issue of SEK 29.2 Million

Sep 9, 2026

Closed 0.329 (-21.7%) on Sep 10, 2026

Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026

Mar 5, 2026

Closed 0.33 (-5.2%) on Mar 5, 2026

Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center

Dec 15, 2025

Closed 0.56 (+4.1%) on Dec 15, 2025

Biovica Carries Out a Directed Share Issue of Approximately MSEK 42.2

Aug 13, 2025

Biovica announces outcome of rights issue

Aug 5, 2025

Biovica Launches DiviTum(R) TKa for Use in Early Breast Cancer

Jul 25, 2025

Biovica Awarded 3 MSEK Contract - 4th from Leading Tier-1 Pharma Company

Jul 24, 2025

Biovica Granted New European Patent

Jun 26, 2025

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Jun 11, 2025

All Biovica International AB news

Financings

  • Rights offering of b-shares

    Sep 9, 2026 · US$3.05M

    Announced: about SEK 29.2M · SEK 0.3 a share · Zonda Partners AB

    Dealers: Zonda Partners AB

    Buyers: HDF (Subscription commitment (with two other shareholders, about SEK 7.92 million in total) and guarantee undertaking of a maximum of approximately SEK 21.21 million, 72.67 percent of the Rights Issue); Cornelia Willemina Kuijvenhoven (Subscription commitment, part of approximately SEK 7.92 million total with HDF and Cornelis Jan Bogerd); Cornelis Jan Bogerd (Subscription commitment, part of approximately SEK 7.92 million total with HDF and Cornelia Willemina Kuijvenhoven); Cornelis Peter Bogerd (Intends to subscribe for his pro rata share, 0.18 percent of the Rights Issue)

    Insiders: Board member Cornelis Peter Bogerd intends to subscribe for his pro rata share (0.18 percent); CEO Theis Kipling and board members Fredrik Alpsten and Jesper Söderqvist intend to subscribe for about SEK 0.5 million (1.68 percent).

    Use of proceeds: Working capital: about 50 percent to continue US commercialisation of DiviTum TKa and about 50 percent to expand the pharma service offering.

    Announced Sep 9, 2026

Read by 6ix AI from the company's releases

Decks

Biovica International AB on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
4 in the last 12 months · 15 in all · newest Sep 16, 2026 · oldest 2025
Calls
11 calls with a replay · 11 with a transcript · latest Sep 10, 2026
Decks
20 decks · latest Jun 18, 2025

Where Biovica International AB is listed

ListingExchangeCountryCurrency
Stockholm:BIOVICB · Home listingStockholmSwedenSEK
LS Exchange:A2DPS4LS ExchangeGermanyEUR
Lang & Schwarz:A2DPS4Lang & SchwarzGermanyEUR
gettex:9IIgettexGermanyEUR
Munich:9II · This pageMunichGermanyEUR
Frankfurt:9IIFrankfurtGermanyEUR
Stuttgart:9IIStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Biovica International AB.